A new study by HUGHES et al. published in The American Journal of Clinical Nutrition provides evidence that high levels of selenium and selenoprotein P are associated with a decreased risk of developing liver cancer.
The selenium status is suboptimal in many European countries and may be an risk factor for developing various kinds of cancer.
The study determined the prediagnostic selenium status by measuring selenium and selenoprotein P and investigated the association with hepatocellular carcinoma (HCC) and gallbladder and biliary tract cancer (GBTC).
The blood levels of selenoprotein P were measured using the ICI product Selenotest™ ELISA by the Charité Universitätsmedizin Berlin.
The study results showed that higher levels of circulating selenium or selenoprotein P were associated with a significantly lower HCC risk.
The study was based on the EPIC cohort, one the largest cohort studie in the world, with more than half a million (521,000) participants.
The press release No. 245 from 4 July 2016 “Low selenium levels linked to liver cancer development” of the International Agency for Research on Cancer (IARC) can be read here: http://www.iarc.fr/en/media-centre/pr/2016/pdfs/pr245_E.pdf
The study results were published by:
HUGHES D.J., T. DUARTE-SALLES, S. HYBSIER, A. TRICHOPOULOU, M. STEPIEN, K. ALEKSANDROVA, K. OVERVAD, A. TJØNNELAND, A. OLSEN, A. AFFRET, G. FAGHERAZZI, M.C. BOUTRON-RUAULT, V. KATZKE, R. KAAKS, H. BOEING, C. BAMIA, P. LAGIOU, E. PEPPA, D. PALLI, V. KROGH, S. PANICO, R. TUMINO, C. SACERDOTE, H.B. BUENO-DE-MESQUITA, P.H. PEETERS, D. ENGESET, E. WEIDERPASS, C. LASHERAS, A. AGUDO, M.J. SÁNCHEZ, C. NAVARRO, E. ARDANAZ, M. DORRONSORO, O. HEMMINGSSON, N.J. WAREHAM, K.T. KHAW, K.E. BRADBURY, A.J. CROSS, M. GUNTER, E. RIBOLI, I. ROMIEU, L. SCHOMBURG and M. JENAB.
Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort.
Am J Clin Nutr. 2016, Jun 29.
Available from: http://dx.doi.org/10.3945/ajcn.116.131672